… to execute on our strategy.” Recent Progress Continue to advance AX-0810 for patients suffering from cholestatic … cardiovascular risk. ProQR plans to present and publish additional preclinical data from these two pipeline programs … Chardan Genetic Medicines Conference panel discussion on “ ADAR RNA Editing: Unlocking New Therapeutic Opportunities ”. …
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
… ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides … the Company’s runway and deliver on its commitment to advance RNA therapies for diseases with high unmet need. … in 2014, it has established a leading IP estate in the ADAR editing space, a first industry partnership, and with …
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026